

Contents

Foreword — V

List of abbreviations — XXI

Definition of cytoreduction, NCCN-Guidelines — XXV

Immunohistochemistry table — XXVI

Volume 1

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

- 1 Variants of leiomyoma (angio- and lipoleiomyoma, cotyledonoid and cellular leiomyoma, leiomyoma with bizarre nuclei, mitotically active, epithelioid and myxoid leiomyoma), smooth muscle tumors with uncertain malignant potential (atypical smooth muscle tumors), disseminated peritoneal leiomyomatosis, benign metastasizing leiomyoma, intravenous leiomyomatosis — 1**
 - 1.1 Angioleiomyoma (Angiomyoma, vascular leiomyoma) — 1**
 - 1.1.1 General, epidemiology, etiology, pathogenesis, pathological-anatomical findings — 1**
 - 1.1.2 Clinical presentation, diagnostics, imaging, differential diagnostics — 3**
 - 1.1.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — 5**
 - 1.1.4 Aftercare, recurrences, metastases and their treatment — 6**
 - 1.2 Lipoleiomyoma — 6**
 - 1.2.1 General, pathogenesis, pathological-anatomical findings — 6**
 - 1.2.2 Clinical presentation, diagnostics, imaging, differential diagnostics — 7**
 - 1.2.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — 8**
 - 1.3 Cotyledonoid dissecting leiomyoma — 8**
 - 1.3.1 General, pathogenesis, pathological-anatomical findings — 8**
 - 1.3.2 Clinical presentation, diagnostics, imaging, differential diagnostics — 9**
 - 1.3.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — 9**

1.4	Cellular leiomyoma — 10
1.4.1	General, pathogenesis, pathological-anatomical findings — 10
1.4.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 13
1.4.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 19
1.4.4	Aftercare, recurrences, metastases — 22
1.5	Leiomyoma with bizarre nuclei — 23
1.5.1	General, pathogenesis, pathological-anatomical findings — 23
1.5.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 26
1.5.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 26
1.6	Mitotically active leiomyoma — 27
1.6.1	General, pathogenesis, pathological-anatomical findings — 27
1.6.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 28
1.6.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 30
1.7	Epithelioid leiomyoma — 30
1.7.1	General, pathogenesis, pathological-anatomical findings — 30
1.7.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 32
1.7.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 33
1.8	Myxoid leiomyoma — 33
1.8.1	General, pathogenesis, pathological-anatomical findings — 33
1.8.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 35
1.8.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 35
1.9	Atypical smooth muscle tumors (smooth muscle tumors with uncertain malignant potential – STUMP), epithelioid and myxoid leiomyoma with uncertain malignant potential — 36
1.9.1	General, pathogenesis, pathological-anatomical findings — 36
1.9.2	Clinical presentation, diagnostics, imaging, differential diagnostics — 43
1.9.3	Course, prognosis, primary surgery, systemic and radiogenic therapy — 47
1.9.4	Aftercare and follow-up, recurrences, metastases and their treatment — 53

- 1.10 Leiomyoma, its variants and smooth muscle tumors with uncertain malignant potential of the vulva — **56**
 - 1.10.1 General, pathogenesis, pathological-anatomical findings — **56**
 - 1.10.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **57**
 - 1.10.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **58**
- 1.11 Ovarian and tubal leiomyomas, their variants and smooth muscle tumors with uncertain malignant potential — **59**
 - 1.11.1 General, pathogenesis, pathological-anatomical findings — **59**
 - 1.11.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **60**
 - 1.11.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **61**
- 1.12 Retroperitoneal and vaginal pelvic leiomyomas, their variants and smooth muscle tumors with uncertain malignant potential — **62**
 - 1.12.1 General, pathogenesis, pathological-anatomical findings — **62**
 - 1.12.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **62**
 - 1.12.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **65**
- 1.13 Disseminated (diffuse) peritoneal leiomyomatosis (Leiomyomatosis peritonealis disseminata) and parasitic leiomyoma — **65**
 - 1.13.1 General, pathogenesis, pathological-anatomical findings — **65**
 - 1.13.2 Clinical features, diagnostics, imaging, differential diagnostics — **72**
 - 1.13.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **76**
 - 1.13.4 Aftercare, recurrences, metastases, surgical management and postoperative additive therapy for recurrences and metastatic disease — **79**
- 1.14 Benign metastasizing leiomyoma (MLM) — **81**
 - 1.14.1 General, pathogenesis, pathological-anatomical findings — **81**
 - 1.14.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **84**
 - 1.14.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **88**
 - 1.14.4 Aftercare, recurrences, metastases, surgical management and postoperative additive therapy for recurrences and metastatic disease — **92**
- 1.15 Intravenous (intravascular) leiomyomatosis (IVLM) — **92**
 - 1.15.1 General, pathogenesis, pathological-anatomical findings — **92**

- 1.15.2 Clinical presentation, diagnostics, imaging, differential diagnostic — **95**
- 1.15.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **98**
- 1.15.4 Aftercare, recurrences, metastases, surgical management and postoperative additive therapy for recurrences and metastatic disease — **101**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

2 Leiomyosarcoma — 119

- 2.1 Uterine leiomyosarcoma — **119**
 - 2.1.1 General, epidemiology, etiology, pathogenesis, staging — **119**
 - 2.1.2 Macroscopic and microscopic features — **124**
 - 2.1.3 Clinical presentation, diagnostics, screening — **134**
 - 2.1.4 Imaging — **139**
 - 2.1.5 Differential diagnostics — **150**
 - 2.1.6 Course, prognosis — **155**
 - 2.1.7 Primary surgery — **161**
 - 2.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **166**
 - 2.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **170**
 - 2.1.10 Aftercare, recurrences, metastases — **172**
 - 2.1.11 Surgical management and postoperative additive therapy for recurrences and metastatic disease — **177**
 - 2.1.12 Palliative radio-, chemo- and hormone therapy, treatment with small molecules, supportive therapy — **184**
- 2.2 Leiomyosarcoma of the ovary — **192**
 - 2.2.1 General, epidemiology, etiology, pathogenesis, staging, pathological-anatomical findings — **192**
 - 2.2.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **194**
 - 2.2.3 Course, prognosis, primary surgery, adjuvant and additive radio- and chemotherapy — **194**
- 2.3 Leiomyosarcoma of the fallopian tube — **196**
 - 2.3.1 General, pathogenesis, pathological-anatomical findings — **196**
 - 2.3.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **196**
 - 2.3.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **196**
- 2.4 Leiomyosarcoma of the uterine, pelvic and ovarian veins — **197**
 - 2.4.1 General, pathogenesis, staging, pathological-anatomical findings — **197**

- 2.4.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **197**
- 2.4.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **198**
- 2.5 Leiomyosarcoma of the vagina — **199**
- 2.5.1 General, pathogenesis, staging, pathological-anatomical findings — **199**
- 2.5.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **200**
- 2.5.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **201**
- 2.6 Leiomyosarcoma of the vulva — **203**
- 2.6.1 General, pathogenesis, pathologic-anatomical features — **203**
- 2.6.2 Clinical presentation, diagnostics, imaging, differential diagnostics — **205**
- 2.6.3 Course, prognosis, primary surgery, systemic and radiogenic therapy — **206**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

- 3 Endometrial stromal tumors – endometrial stromal nodule, endometrial stromal tumor with sex cord-like elements (ESTSCLE), uterine tumor resembling ovarian sex-cord tumor (UTROSCT) and similar tumors — 231**
- 3.1 Endometrial stromal nodule — **231**
- 3.1.1 Uterine endometrial stromal nodule — **231**
- 3.1.2 Extrauterine endometrial stromal nodules — **243**
- 3.2 Special variants of endometrial stromal tumors — **243**
- 3.2.1 Endometrial stromal tumor with endometrioid glands — **243**
- 3.2.2 Mixed endometrial stromal and smooth muscle tumor, combined stromal-smooth muscle — **243**
- 3.2.3 Uterine tumor with sex cord-like elements type I (ESTSCLE, endometrial stromal tumor with sex cord-like elements) — **244**
- 3.2.4 Uterine tumors with sex cord-like elements type II (UTROSCT, uterine tumors resembling ovarian sex-cord tumors) — **247**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

- 4 Low-grade endometrial stromal sarcoma — 257**
- 4.1 Uterine low-grade endometrial stromal sarcoma — **257**
- 4.1.1 General, epidemiology, etiology, pathogenesis, staging — **257**
- 4.1.2 Macroscopic and microscopic features — **260**
- 4.1.3 Clinical presentation, diagnostics, screening — **267**
- 4.1.4 Imaging — **270**

- 4.1.5 Differential diagnostics — **279**
- 4.1.6 Course, prognosis — **282**
- 4.1.7 Primary surgery — **288**
- 4.1.8 Adjuvant and additive radio-, chemo- and hormone therapy — **291**
- 4.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **296**
- 4.1.10 Aftercare, recurrences, metastases — **298**
- 4.1.11 Surgical management and postoperative additive therapy for recurrences and metastatic disease — **301**
- 4.1.12 Palliative radio-, chemo- and hormone therapy, treatment with small molecules, supportive therapy — **304**
- 4.2 Extrauterine endometrial stromal sarcomas — **309**

Günter Köhler, Katja Evert, Marek Zygmunt and Matthias Evert

5 High-grade endometrial stromal sarcoma and undifferentiated uterine sarcoma — 327

- 5.1 Uterine high-grade endometrial stromal sarcoma and undifferentiated uterine sarcoma — **327**
 - 5.1.1 General, epidemiology, etiology, pathogenesis, staging — **327**
 - 5.1.2 Macroscopic and microscopic features — **329**
 - 5.1.3 Clinical presentation, diagnostics, screening — **335**
 - 5.1.4 Imaging — **336**
 - 5.1.5 Differential diagnostics — **343**
 - 5.1.6 Course, prognosis — **346**
 - 5.1.7 Primary surgery — **349**
 - 5.1.8 Adjuvant and additive radio, chemo and hormone therapy — **351**
 - 5.1.9 Primary radio-, chemo- and hormone therapy, approach in cases of general inoperability — **354**
 - 5.1.10 Aftercare, recurrences, metastases — **356**
 - 5.1.11 Surgical management and postoperative additive therapy for recurrences and metastatic disease — **358**
 - 5.1.12 Palliative radio-, chemo- and hormone therapy, treatment with small molecules, supportive therapy — **361**
- 5.2 Extrauterine high-grade endometrial stromal sarcomas and undifferentiated uterine sarcomas — **365**

Günter Köhler, Lars Kaderali, Matthias Evert and Marek Zygmunt

6 Prevention of inadequate sarcoma operations — 373

- 6.1 Inadequate surgical treatment of uterine sarcomas in leiomyoma surgery — **373**
- 6.2 Inadequate surgical treatment of sarcomas and STUMP – impact on prognosis — **373**

6.3	Prevalence of uterine sarcomas in hysterectomies and surgery performed under the indication of leiomyoma — 380
6.4	Anamnestic and clinical criteria suggestive of uterine sarcoma in cases of supposed leiomyoma — 382
6.5	Further, extended diagnostics when there are findings suggestive of uterine sarcoma in cases of assumed leiomyoma — 388
6.6	Diagnostic flowchart for preventing the performance of inadequate surgery on sarcomas under an assumed indication of leiomyoma — 395
6.7	Risk assessment as a decision-making aid when surgery is planned under an indication of leiomyoma — 398
6.8	Measures to be applied when sarcoma have been subjected to inadequate surgery under an indication of leiomyoma — 400
Index — 411	